Nano-X Imaging (NNOX) Investor Summit Virtual Conference summary
Event summary combining transcript, slides, and related documents.
Investor Summit Virtual Conference summary
25 Mar, 2026Company overview and product strategy
Provides an end-to-end imaging solution from scan to diagnosis, aiming to enhance diagnostic capabilities for patients.
Core product is the Nanox.ARC, a digital multi-source 3D tomosynthesis imaging system, with both first and second generation devices (ARC and ARC X) FDA-cleared.
Recent acquisition of VasoHealthcare IT expands the AI and software division, integrating PACS and teleradiology offerings.
Commercialization began in the U.S. in 2023, with European commercialization starting in 2024; direct and indirect sales models in the U.S., indirect (distributor) model elsewhere.
Focuses on imaging centers, urgent care, orthopedic, and multipurpose clinics to avoid direct competition with larger industry players.
Technology and innovation
Proprietary silicon-based, low-voltage, nanoscale cold cathode chip powers the imaging devices, offering cost and operational advantages over traditional X-ray technology.
Second generation tubes use glass instead of ceramic, reducing size and complexity; devices are compact, lightweight, and require minimal installation space.
Multi-source, multi-axis design enables rapid 3D imaging with lower radiation and power requirements compared to CT.
Cloud-based reconstruction software creates 3D images from 30-60 2D scans in under 12 seconds.
Devices are easy to operate, maintain, and integrate with existing PACS systems; remote monitoring and updates are provided.
AI and software solutions
AI tools are FDA and CE approved, supporting early detection of asymptomatic chronic diseases and preventative management.
AI division offers solutions for coronary artery calcium scoring, spinal measurement (HealthOST), bone mineral density, and liver disease detection.
Largest AI customer is Spectrum Health, now in its fifth year; new B2B2C models are being piloted with diagnostic centers.
Acquisition of VasoHealthcare IT enables cross-selling of PACS software and a more comprehensive solution suite.
Latest events from Nano-X Imaging
- Q4 2024 revenue reached $3.0M, but net loss increased to $14.1M as expansion accelerated.NNOX
Q4 202417 Mar 2026 - Revenue up to $2.8M, net loss widens, over 60 ARC units deployed, FDA clearance boosts outlook.NNOX
Q1 202517 Mar 2026 - Q2 2025 revenue rose to $3.0M, net loss increased to $14.7M, and 100+ installations targeted.NNOX
Q2 202517 Mar 2026 - Registration covers up to $100M in securities to fund global imaging and AI expansion.NNOX
Registration Filing13 Mar 2026 - Expanded deployments, new FDA clearances, and improved financials mark a strong Q2 2024.NNOX
Q2 202423 Jan 2026 - 3D X-ray imaging with AI and cloud updates drives global growth and access in medical imaging.NNOX
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 saw $3.0M revenue, narrowed net loss, and strong teleradiology and AI growth.NNOX
Q3 202412 Jan 2026 - Mobile 3D imaging and AI tools drive commercial growth and strong market interest.NNOX
Sidoti's Year End Virtual Investor Conference12 Dec 2025 - Q3 2025 revenue reached $3.4M; VasoHealthcare IT deal and global growth drive 2026 outlook.NNOX
Q3 202520 Nov 2025